{"id":3506,"date":"2010-09-24T08:24:05","date_gmt":"2010-09-24T12:24:05","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?p=3506"},"modified":"2011-07-19T17:44:47","modified_gmt":"2011-07-19T21:44:47","slug":"xience-v-stent-still-strong-at-2-years","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2010\/09\/24\/xience-v-stent-still-strong-at-2-years\/","title":{"rendered":"Xience V Stent Still Strong at 2 Years"},"content":{"rendered":"<p>Two large trials presented at TCT continue to demonstrate the long-term superiority of the everolimus-eluting stent (EES) over the paclitaxel-eluting stent (PES).<\/p>\n<p><a href=\"http:\/\/www.tctconference.com\/mobileslides\/SPIRIT_IV.pdf\">Gregg Stone presented\u00a0two-year outcomes<\/a> from more than 3500 patients randomized in the SPIRIT IV trial\u00a0to either the Xience V or the Taxus stents. At two years, the rate of target lesion failure \u2014 defined as cardiac death, target vessel MI, or ischemia-driven target lesion revascularization \u2014 was 9.9% in the Taxus group compared to 6.9% in the Xience V group (p&lt;0.003). The rate of stent thrombosis was 1.25% in the Taxus group compared to 0.33% in the Xience V group (p=0.002).<\/p>\n<p>In the\u00a0<a href=\"http:\/\/www.tctconference.com\/mobileslides\/COMPARE.pdf\">two-year followup of the COMPARE trial<\/a>, which included nearly 1800 patients,\u00a0Peter Smits reported that the rate of death, nonfatal MI, and TVR was 13.7% in the Taxus group compared to 9.0% in the Xience group (p=0.0016). Definite or probable stent thrombosis was 3.9% in the Taxus group compared to 0.9% in the Xience group (p&lt;0.0001).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Two large trials presented at TCT continue to demonstrate the long-term superiority of the everolimus-eluting stent (EES) over the paclitaxel-eluting stent (PES). Gregg Stone presented\u00a0two-year outcomes from more than 3500 patients randomized in the SPIRIT IV trial\u00a0to either the Xience V or the Taxus stents. At two years, the rate of target lesion failure \u2014 [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[331,435,436,437,434,433],"class_list":["post-3506","post","type-post","status-publish","format-standard","hentry","category-general","tag-des","tag-ees","tag-pes","tag-stents","tag-taxus","tag-xience-v"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/3506","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=3506"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/3506\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=3506"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=3506"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=3506"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}